KLF2 and endothelial dysfunction: KLF2 activation (by atorvastatin and tannic acid, a natural KLF2 activator) and KLF2 overexpression (by KLF2 adenovirus) have been proven to significantly reduce patient-serum-induced monocyte adhesion to endothelial cells and have therapeutic potential in limiting endothelial dysfunction [99].